IL194775A - Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention - Google Patents

Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention

Info

Publication number
IL194775A
IL194775A IL194775A IL19477508A IL194775A IL 194775 A IL194775 A IL 194775A IL 194775 A IL194775 A IL 194775A IL 19477508 A IL19477508 A IL 19477508A IL 194775 A IL194775 A IL 194775A
Authority
IL
Israel
Prior art keywords
caveolae
dysfunction
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
IL194775A
Other languages
English (en)
Hebrew (he)
Other versions
IL194775A0 (en
Original Assignee
Lantmannen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmannen As Faktor Ab filed Critical Lantmannen As Faktor Ab
Publication of IL194775A0 publication Critical patent/IL194775A0/en
Publication of IL194775A publication Critical patent/IL194775A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL194775A 2006-04-27 2008-10-22 Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention IL194775A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0600933 2006-04-27
US92082607P 2007-03-30 2007-03-30
PCT/SE2007/000415 WO2007126365A2 (en) 2006-04-27 2007-04-27 Further medical uses of antisecretory protein

Publications (2)

Publication Number Publication Date
IL194775A0 IL194775A0 (en) 2011-08-01
IL194775A true IL194775A (en) 2015-09-24

Family

ID=38655930

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194775A IL194775A (en) 2006-04-27 2008-10-22 Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention

Country Status (10)

Country Link
US (1) US8487074B2 (https=)
EP (1) EP2037950B1 (https=)
JP (2) JP5508846B2 (https=)
KR (1) KR20090037992A (https=)
AU (1) AU2007244005B2 (https=)
CA (1) CA2650132C (https=)
IL (1) IL194775A (https=)
MX (1) MX2008013777A (https=)
PL (1) PL2037950T3 (https=)
WO (1) WO2007126365A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013769A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Uso de factores antisecretores para el tratamiento de hipertension intraocular.
MX2008013777A (es) 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
KR101757523B1 (ko) 2006-04-27 2017-07-12 란트만넨 아스-팍토르 아베 구획 증후군의 치료에 사용하기 위한 항분비 단백질
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010093324A1 (en) * 2009-02-11 2010-08-19 Lantmännen As-Faktor Ab Use of antisecretory factors (af) for optimizing cellular uptake
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
US11253552B2 (en) 2015-07-10 2022-02-22 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of AF-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
JP7217760B2 (ja) * 2018-06-28 2023-02-03 ラントメネン・メディカル・アーベー 急性呼吸不全の治療および／または予防の使用のための抗分泌因子
WO2022159845A1 (en) * 2021-01-22 2022-07-28 University Of Virginia Patent Foudation Altering protein function by pharmacological targeting of membrane domains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
MX2008013777A (es) 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
KR101757523B1 (ko) * 2006-04-27 2017-07-12 란트만넨 아스-팍토르 아베 구획 증후군의 치료에 사용하기 위한 항분비 단백질
EP2682819A2 (en) * 2012-07-04 2014-01-08 Xeikon IP B.V. A method for forming a multi-colour image

Also Published As

Publication number Publication date
IL194775A0 (en) 2011-08-01
CA2650132A1 (en) 2007-11-08
AU2007244005B2 (en) 2012-08-02
HK1128237A1 (en) 2009-10-23
EP2037950A2 (en) 2009-03-25
KR20090037992A (ko) 2009-04-17
JP2009535330A (ja) 2009-10-01
WO2007126365A8 (en) 2009-03-05
EP2037950B1 (en) 2014-04-23
AU2007244005A1 (en) 2007-11-08
JP2014111623A (ja) 2014-06-19
JP5508846B2 (ja) 2014-06-04
WO2007126365A3 (en) 2008-03-13
US20090149382A1 (en) 2009-06-11
US8487074B2 (en) 2013-07-16
CA2650132C (en) 2017-10-24
WO2007126365A2 (en) 2007-11-08
PL2037950T3 (pl) 2014-09-30
MX2008013777A (es) 2009-02-03
JP6063401B2 (ja) 2017-01-18

Similar Documents

Publication Publication Date Title
IL194775A (en) Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention
ZA200900388B (en) Compositions and methods for the treatment of mucositis
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
IL197275A0 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP1940361A4 (en) PHARMACEUTICAL DOSAGE FORMS HAVING CONTROLLED AND / OR IMMEDIATE RELEASE PROPERTIES
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
CA2645871A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
PL1794174T3 (pl) Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
IL198847A (en) Process for making 2-imino-thiazolidine-4-on and several such histories
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
IL204741A (en) Ceramide History for the Treatment of Multiple Cyst Diseases and Pharmaceuticals Containing These History
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
IL197236A (en) Pharmaceuticals containing Almatosumab and uses of Almatosumab for the preparation of pharmaceuticals to reduce the risk of MS
PT1938684E (pt) Utilização de polioximetilenodialquiléteres e/ou de acetais de dialdeído para a preservação de corpos humanos ou animais, e composições contendo-os
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
ZA200900231B (en) (S)-(-)-amlodipine camsylate or hydrate thereof and pharmaceutical composition comprising same
GB0614365D0 (en) Pharmaceutical compositions and their use
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed